0.7735
0.0000
(0.00%)
As of April 8 at 4:00:00 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Brian Firth | CEO & Director | 73.96k | -- | -- |
Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | CFO & Company Secretary | 40.57k | -- | 1960 |
Dr. Robert Crandall Greene | CTO & Director | 110.52k | -- | -- |
Mr. Hugh McNaught | VP of Marketing & Member of Advisory Board | -- | -- | -- |
Mr. David Browning FCIM, M.Sc. | Head of Productization & Director of Gemina Laboratories (UK) Limited | -- | -- | -- |
Dr. Christine Buerki Ph.D. | Head of Product Development | -- | -- | -- |
Gemina Laboratories Ltd.
3600 Gilmore Way
Unit 302
Burnaby, BC V5G 4W8
Canada
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It is developing respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.
Corporate Governance
Gemina Laboratories Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 30, 2025 at 8:00 PM UTC - June 4, 2025 at 8:00 PM UTC
Gemina Laboratories Ltd. Earnings Date
Recent Events
Recent Events Information Not Available